Do analysts rate INS or KOO?

Kooth has a consensus price target of GBX 330, suggesting a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Instem. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, INS or KOO?

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instem £61.63M 0.00 £3.34M £0.14 N/A Kooth £63.29M 0.87 £4.00M £7.00 21.57

Is INS or KOO more profitable?

Instem has a net margin of 5.50% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Instem's return on equity. Company Net Margins Return on Equity Return on Assets Instem 5.50% 6.35% 4.62% Kooth 4.12% 8.84% 10.12%

Does the media favor KOO or COG?

In the previous week, Kooth had 3 more articles in the media than Cambridge Cognition. MarketBeat recorded 4 mentions for Kooth and 1 mentions for Cambridge Cognition. Kooth's average media sentiment score of 0.21 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kooth 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cambridge Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer KOO or RENX?

Kooth currently has a consensus price target of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts clearly believe Kooth is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, KOO or RENX?

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 0.87 £4.00M £7.00 21.57 Renalytix £3.30M 3.77 -£109.93M -£4.00 N/A

Is KOO or RENX more profitable?

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 4.12% 8.84% 10.12% Renalytix -506.25% 675.00% -93.54%

Do analysts prefer KOO or INHC?

Kooth currently has a consensus price target of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer KOO or FDBK?

Kooth presently has a consensus target price of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher probable upside, equities analysts clearly believe Kooth is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, KOO or FDBK?

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 0.87 £4.00M £7.00 21.57 Feedback £849.62K 3.15 -£10.84M -£15.74 N/A

Is KOO or FDBK more profitable?

Kooth has a net margin of 4.12% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 8.84% beat Feedback's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 4.12% 8.84% 10.12% Feedback -845.25% -135.17% -22.99%

Kooth (KOO) Competitors

GBX 151 +1.00 (+0.67%)

As of 11:18 AM Eastern

Compare

KOO vs. INS, COG, RENX, INHC, and FDBK

Should you buy Kooth stock or one of its competitors? MarketBeat compares Kooth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kooth include Instem (INS), Cambridge Cognition (COG), Renalytix (RENX), Induction Healthcare Group (INHC), and Feedback (FDBK).

How does Kooth compare to Instem?

Instem (LON:INS) and Kooth (LON:KOO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instem	£61.63M	0.00	£3.34M	£0.14	N/A
Kooth	£63.29M	0.87	£4.00M	£7.00	21.57

Instem has a net margin of 5.50% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Instem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instem	5.50%	6.35%	4.62%
Kooth	4.12%	8.84%	10.12%

In the previous week, Kooth had 4 more articles in the media than Instem. MarketBeat recorded 4 mentions for Kooth and 0 mentions for Instem. Kooth's average media sentiment score of 0.21 beat Instem's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.

Company	Overall Sentiment
Instem	Neutral
Kooth	Neutral

Instem has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Kooth has a beta of 1.299, indicating that its stock price is 30% more volatile than the broader market.

Kooth has a consensus price target of GBX 330, suggesting a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Instem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

65.9% of Instem shares are held by institutional investors. Comparatively, 21.0% of Kooth shares are held by institutional investors. 30.0% of Instem shares are held by company insiders. Comparatively, 30.4% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Kooth beats Instem on 12 of the 15 factors compared between the two stocks.

How does Kooth compare to Cambridge Cognition?

Kooth (LON:KOO) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.87	£4.00M	£7.00	21.57
Cambridge Cognition	£9.40M	1.85	-£1.58M	-£3.90	N/A

Kooth has a beta of 1.299, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.804, suggesting that its share price is 20% less volatile than the broader market.

21.0% of Kooth shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 30.4% of Kooth shares are owned by insiders. Comparatively, 2.8% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kooth currently has a consensus price target of GBX 330, suggesting a potential upside of 118.54%. Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 73.32%. Given Kooth's higher possible upside, equities research analysts clearly believe Kooth is more favorable than Cambridge Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kooth had 3 more articles in the media than Cambridge Cognition. MarketBeat recorded 4 mentions for Kooth and 1 mentions for Cambridge Cognition. Kooth's average media sentiment score of 0.21 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kooth	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cambridge Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kooth beats Cambridge Cognition on 14 of the 15 factors compared between the two stocks.

How does Kooth compare to Renalytix?

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Kooth had 4 more articles in the media than Renalytix. MarketBeat recorded 4 mentions for Kooth and 0 mentions for Renalytix. Kooth's average media sentiment score of 0.21 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Neutral
Renalytix	Neutral

Kooth currently has a consensus price target of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts clearly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Renalytix	-506.25%	675.00%	-93.54%

21.0% of Kooth shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 30.4% of Kooth shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.87	£4.00M	£7.00	21.57
Renalytix	£3.30M	3.77	-£109.93M	-£4.00	N/A

Kooth has a beta of 1.299, indicating that its share price is 30% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Summary

Kooth beats Renalytix on 13 of the 16 factors compared between the two stocks.

How does Kooth compare to Induction Healthcare Group?

Kooth (LON:KOO) and Induction Healthcare Group (LON:INHC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Kooth currently has a consensus price target of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has a beta of 1.299, meaning that its share price is 30% more volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market.

In the previous week, Kooth had 4 more articles in the media than Induction Healthcare Group. MarketBeat recorded 4 mentions for Kooth and 0 mentions for Induction Healthcare Group. Kooth's average media sentiment score of 0.21 beat Induction Healthcare Group's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Neutral
Induction Healthcare Group	Neutral

Kooth has a net margin of 4.12% compared to Induction Healthcare Group's net margin of -23.86%. Kooth's return on equity of 8.84% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Induction Healthcare Group	-23.86%	-14.58%	-7.32%

21.0% of Kooth shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 30.4% of Kooth shares are held by company insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kooth has higher revenue and earnings than Induction Healthcare Group. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.87	£4.00M	£7.00	21.57
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A

Summary

Kooth beats Induction Healthcare Group on 14 of the 16 factors compared between the two stocks.

How does Kooth compare to Feedback?

Kooth (LON:KOO) and Feedback (LON:FDBK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Kooth presently has a consensus target price of GBX 330, indicating a potential upside of 118.54%. Given Kooth's stronger consensus rating and higher probable upside, equities analysts clearly believe Kooth is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.87	£4.00M	£7.00	21.57
Feedback	£849.62K	3.15	-£10.84M	-£15.74	N/A

Kooth has a beta of 1.299, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, Kooth had 4 more articles in the media than Feedback. MarketBeat recorded 4 mentions for Kooth and 0 mentions for Feedback. Kooth's average media sentiment score of 0.21 beat Feedback's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Neutral
Feedback	Neutral

21.0% of Kooth shares are owned by institutional investors. Comparatively, 34.2% of Feedback shares are owned by institutional investors. 30.4% of Kooth shares are owned by company insiders. Comparatively, 8.0% of Feedback shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kooth has a net margin of 4.12% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 8.84% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Feedback	-845.25%	-135.17%	-22.99%

Summary

Kooth beats Feedback on 14 of the 16 factors compared between the two stocks.

Get Kooth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOO vs. The Competition

Export

Metric	Kooth	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£54.77M	£1.39B	£6.80B	£2.83B
Dividend Yield	N/A	4.76%	2.59%	6.15%
P/E Ratio	21.57	275.75	282.15	368.41
Price / Sales	0.87	59.22	571.19	83,654.70
Price / Cash	5.42	30.56	28.64	27.89
Price / Book	2.34	4.69	11.03	7.06
Net Income	£4.00M	-£25.90M	£3.49B	£5.89B
7 Day Performance	-3.30%	1.11%	0.31%	0.21%
1 Month Performance	-6.21%	-3.07%	-4.41%	0.22%
1 Year Performance	-4.54%	-18.79%	62.76%	64.12%

Kooth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOO Kooth	2.6588 of 5 stars	GBX 151 +0.7%	GBX 330 +118.5%	-5.2%	£54.77M	£63.29M	21.57	478
INS Instem	N/A	N/A	N/A	N/A	£199.62M	£61.63M	5,928.57	500
COG Cambridge Cognition	1.1762 of 5 stars	GBX 33 +1.5%	GBX 56 +69.7%	+33.1%	£17.54M	£9.40M	N/A	80
RENX Renalytix	N/A	GBX 2.57 -3.1%	N/A	-63.1%	£11.58M	£3.30M	N/A	102	Gap Down
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:KOO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kooth (KOO) Competitors